A multi‐omic single cell sequencing approach to develop a <scp>CD8</scp> T cell specific gene signature for <scp>anti‐PD1</scp> response in solid tumors-Reference-Cited by-同舟云学术

A multi‐omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti‐PD1 response in solid tumors

Published:2022-08-06 Issue:11 Volume:151 Page:2043-2054
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Kumar Namit¹,Papillon‐Cavanagh Simon¹,Tang Hao¹,Wang Shiliang¹,Stromko Caitlyn¹,Ho Ching‐Ping¹,Soni‐Sheth Sonal¹,Vasquez‐Grinnell Steven¹,Broz Miranda L.¹,Tenney Daniel J.¹,Wichroski Michael J.¹,Walsh Alice M.¹,Hu Yanhua¹,Benci Joseph L.¹^ORCID

Affiliation:

1. Bristol Myers Squibb: Research & Early Development Princeton New Jersey USA

Funder

Bristol Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34218

Reference31 articles.

1. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

2. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

3. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future

4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

5. Immuno-Oncology: Emerging Targets and Combination Therapies

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity;Cell;2024-06

2. Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy;Frontiers in Immunology;2022-11-03